# A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

> **NCT05026229** · NA · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 60 (estimated)

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Philadelphia-Positive Acute Lymphoblastic Leukemia
- ALL, Adult

## Interventions

- **DRUG:** dasatinib plus consolidation chemotherapy with vincristine and prednisone
- **DRUG:** dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine

## Key facts

- **NCT ID:** NCT05026229
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-06
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026229, "A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05026229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*